The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans

This study is currently recruiting participants.

Verified by Glostrup University Hospital,Copenhagen, October 2005

First Received: January 6, 2006 Last Updated: September 7, 2006 History of Changes

Sponsors and Collaborators:	Glostrup University Hospital,Copenhagen Rigshospitalet, Denmark University of Copenhagen
Information provided by:	Glostrup University Hospital,Copenhagen
ClinicalTrials.gov Identifier:	NCT00273000

Purpose

The purpose of this study is to study the effect of GLP-2 on mesenteric bloodflow in healthy adults by the use of ultrasound., it is the hypothesis that GLP-2 vil increase the bloodflow.

Condition	Intervention
Healthy	Drug: GLP-2

Study Type:	Interventional
Study Design:	Health Services Research, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Pharmacokinetics/Dynamics Study
Official Title:	The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans

Resource links provided by NLM:

Drug Information available for: Glucagon

U.S. FDA Resources

Further study details as provided by Glostrup University Hospital,Copenhagen:

Estimated Enrollment:	10
Study Start Date:	January 2006

Detailed Description:

The investigation will include 10 testpersons.

It will be a 2 fase study over 2 days.

day 1: The testperson will meet fasting, and take in a standard liquid meal, after this the bloodflow in a mesenteric artery will be measured by use of ultrasonic technique. Bloodsamples will be taken regular in a total wolumne of 200 ml.

day 2:The testperson will meet fasting, there wil be administered intraveneous GLP-2 in 3 increasing doses over 3 x 45 min.and one subcutaneous dose. During this the bloodflow in a mesenteric artery will be measured by use of ultrasonic technique. Bloodsamples will be taken regular in a total wolumne of 200 ml.

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

healthy

Exclusion Criteria:

use of drugs

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00273000

Contacts

Contact: Lasse Bremholm Hansen, MD

004560927874

hoersted-bremholm@webspeed.dk

Locations

Denmark, Copenhagen City
Rigshospitalet	Recruiting
Copenhagen, Copenhagen City, Denmark, 2100
Contact: Lasse Bremholm Hansen, MD 004560927874 hoersted-bremholm@webspeed.dk
Sub-Investigator: Mads Hornum, MD

Sponsors and Collaborators

Glostrup University Hospital,Copenhagen

Rigshospitalet, Denmark

University of Copenhagen

Investigators

Principal Investigator:

Mads Hornum, MD

Glostrup University Hospital,Copenhagen

More Information

No publications provided

Study ID Numbers:	GLP-2, MBF
Study First Received:	January 6, 2006
Last Updated:	September 7, 2006
ClinicalTrials.gov Identifier:	NCT00273000 History of Changes
Health Authority:	Denmark: National Board of Health

Study placed in the following topic categories:

Glucagon
Healthy

ClinicalTrials.gov processed this record on September 01, 2009